International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Laboratory Center

国际孕产妇儿科青少年艾滋病临床试验(IMPAACT)实验室中心

基本信息

项目摘要

DESCRIPTION (provided by the applicant): The designated laboratories of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network have been integral to its success in defining the standards of care for HIV infected pregnant women, children and adolescents. IMPAACT laboratory studies have elucidated the pathogenesis of HIV transmission, improved strategies designed to interrupt mother-to-child transmission (MTCT), optimized HIV treatment even in the setting of multi-drug resistance, and enhanced the diagnosis, prevention and management of HIV-related complications. The laboratories have been leaders in the development and evaluation of assays for infant diagnosis, viral load monitoring, drug resistance, antiretroviral pharmacology, host genetics and the measurement of immune responses. These studies were performed within the constraints of the small blood volumes available from our study populations and internationally in resource-limited settings. Often new methodologies and novel approaches have been developed to accommodate the limited specimens available from infants, children and pregnant women. In addition, all laboratory studies were performed under a comprehensive Total Quality Management Program that assured the highest standards of laboratory testing. The IMPAACT Network Laboratory Center (LC) is led by Grace Aldrovandi MD, CM, who will work closely with the IMPAACT Leadership Group, the Laboratory Steering Committee and the External Advisory Board to support, synergize and enhance the IMPAACT scientific agenda. The LC has 2 overarching specific aims: (1) Provide laboratory-based scientific leadership, consultation and laboratory capacity, including the development and implementation of innovative assays and protocols to enhance IMPAACT's Research Agenda and seven scientific aims. (2) Provide the technical, regulatory and administrative infrastructure and oversight for all laboratory testing done in support of IMPAACT clinical trials. RELEVANCE: The Laboratory Center will provide laboratory-based scientific leadership, consultation and laboratory capacity, to enhance IMPAACT's Research Agenda and achieve its Scientific Aims. It will also provide the technical, regulatory and administrative infrastructure ad oversight for all laboratory testing done in support of IMPAACT clinical trials. Component 1 - Leadership Group Overview
说明(由申请人提供):国际母婴青少年艾滋病临床试验网络的指定实验室是该网络成功确定感染艾滋病毒的孕妇、儿童和青少年护理标准不可或缺的一部分。该中心的实验室研究阐明了艾滋病毒传播的机制,改进了旨在阻断母婴传播的战略,优化了艾滋病毒治疗,即使在出现多药耐药的情况下也是如此,并加强了艾滋病毒相关并发症的诊断、预防和管理。这些实验室在婴儿诊断、病毒载量监测、耐药性、抗逆转录病毒药理学、宿主遗传学和免疫反应测量的测试开发和评估方面一直处于领先地位。这些研究是在我们的研究人群和国际上资源有限的环境中可获得的小血量的限制下进行的。为了适应婴儿、儿童和孕妇提供的有限标本,往往开发了新的方法和新的方法。此外,所有实验室研究都是在全面质量管理计划下进行的,该计划确保了实验室测试的最高标准。亚太技转中心网络实验室中心由格雷斯·奥尔德罗万迪博士领导,他将与亚太技转中心领导小组、实验室指导委员会和外部咨询委员会密切合作,以支持、协同和加强亚太技转中心的科学议程。该委员会有两个最重要的具体目标:(1)提供以实验室为基础的科学领导、咨询和实验室能力,包括开发和实施创新的分析方法和方案,以加强研究所的研究议程和七个科学目标。(2)为支持IMPAACT临床试验而进行的所有实验室检测提供技术、监管和行政基础设施和监督。 相关性:实验室中心将提供以实验室为基础的科学领导、咨询和实验室能力,以加强IMPAACT的研究议程并实现其科学目标。它还将为支持IMPAACT临床试验的所有实验室测试提供技术、监管和行政基础设施和监督。 组成部分1-领导班子概述

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Grace M Aldrovandi其他文献

Immunomodulatory factors in cervicovaginal secretions from pregnant and non-pregnant women: A cross-sectional study
孕妇和非孕妇宫颈阴道分泌物中的免疫调节因子:横断面研究
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Jan Walter;Linda Fraga;Melanie J Orin;William D Decker;Theresa Gipps;Alice Stek;Grace M Aldrovandi
  • 通讯作者:
    Grace M Aldrovandi

Grace M Aldrovandi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Grace M Aldrovandi', 18)}}的其他基金

Core C -Centralized Laboratory Support Core
核心C - 集中实验室支持核心
  • 批准号:
    10609765
  • 财政年份:
    2022
  • 资助金额:
    $ 178.08万
  • 项目类别:
Study of Tecovirimat for Human Monkeypox Virus (STOMP)
Tecovirimat 针对人猴痘病毒 (STOMP) 的研究
  • 批准号:
    10689623
  • 财政年份:
    2022
  • 资助金额:
    $ 178.08万
  • 项目类别:
Core C -Centralized Laboratory Support Core
核心C - 集中实验室支持核心
  • 批准号:
    10458372
  • 财政年份:
    2022
  • 资助金额:
    $ 178.08万
  • 项目类别:
A5401 COVID Supplement
A5401 新冠肺炎补充剂
  • 批准号:
    10203227
  • 财政年份:
    2020
  • 资助金额:
    $ 178.08万
  • 项目类别:
Effects of Human Milk Oligosaccharides and Gut Microbiome on Growth and Morbidity in HIV-Exposed Uninfected Infants
母乳低聚糖和肠道微生物组对暴露于 HIV 的未感染婴儿生长和发病的影响
  • 批准号:
    9920737
  • 财政年份:
    2019
  • 资助金额:
    $ 178.08万
  • 项目类别:
Effects of Human Milk Oligosaccharides and Gut Microbiome on Growth and Morbidity in HIV-Exposed Uninfected Infants
母乳低聚糖和肠道微生物组对暴露于 HIV 的未感染婴儿生长和发病的影响
  • 批准号:
    10610833
  • 财政年份:
    2019
  • 资助金额:
    $ 178.08万
  • 项目类别:
Effects of Human Milk Oligosaccharides and Gut Microbiome on Growth and Morbidity in HIV-Exposed Uninfected Infants
母乳低聚糖和肠道微生物组对暴露于 HIV 的未感染婴儿生长和发病的影响
  • 批准号:
    10382305
  • 财政年份:
    2019
  • 资助金额:
    $ 178.08万
  • 项目类别:
Maturation, Infectibility, and Trauma(MIT) Contributes to HIV Susceptibility in Adolescents
成熟、传染性和创伤(麻省理工学院)导致青少年对艾滋病毒的易感性
  • 批准号:
    9245320
  • 财政年份:
    2017
  • 资助金额:
    $ 178.08万
  • 项目类别:
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Laboratory Center
国际孕产妇儿科青少年艾滋病临床试验(IMPAACT)实验室中心
  • 批准号:
    9188522
  • 财政年份:
    2016
  • 资助金额:
    $ 178.08万
  • 项目类别:
International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network
国际孕产妇、青少年和儿科治疗临床试验网络
  • 批准号:
    9986166
  • 财政年份:
    2014
  • 资助金额:
    $ 178.08万
  • 项目类别:

相似海外基金

Assessing the Clinical Utility of Proviral DNA-based Antiretroviral Drug Resistance Testing in Individuals Living with Human Immunodeficiency Virus Type 1
评估基于 Proviral DNA 的抗逆转录病毒耐药性检测在 1 型人类免疫缺陷病毒感染者中的临床效用
  • 批准号:
    449333
  • 财政年份:
    2020
  • 资助金额:
    $ 178.08万
  • 项目类别:
    Studentship Programs
Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
  • 批准号:
    8545480
  • 财政年份:
    2013
  • 资助金额:
    $ 178.08万
  • 项目类别:
Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
  • 批准号:
    8894367
  • 财政年份:
    2013
  • 资助金额:
    $ 178.08万
  • 项目类别:
Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
  • 批准号:
    8709982
  • 财政年份:
    2013
  • 资助金额:
    $ 178.08万
  • 项目类别:
Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
  • 批准号:
    9463184
  • 财政年份:
    2013
  • 资助金额:
    $ 178.08万
  • 项目类别:
ANTIRETROVIRAL DRUG RESISTANCE--CLINICAL AND IMMUNE EFFECTS
抗逆转录病毒耐药性——临床和免疫影响
  • 批准号:
    3791777
  • 财政年份:
  • 资助金额:
    $ 178.08万
  • 项目类别:
ANTIRETROVIRAL DRUG RESISTANCE--CLINICAL AND IMMUNE EFFECTS
抗逆转录病毒耐药性——临床和免疫影响
  • 批准号:
    3727424
  • 财政年份:
  • 资助金额:
    $ 178.08万
  • 项目类别:
ANTIRETROVIRAL DRUG RESISTANCE--CLINICAL AND IMMUNE EFFECTS
抗逆转录病毒耐药性——临床和免疫影响
  • 批准号:
    3747322
  • 财政年份:
  • 资助金额:
    $ 178.08万
  • 项目类别:
ANTIRETROVIRAL DRUG RESISTANCE--CLINICAL AND IMMUNE EFFECTS
抗逆转录病毒耐药性——临床和免疫影响
  • 批准号:
    3769657
  • 财政年份:
  • 资助金额:
    $ 178.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了